ArticleBiochemical genetics2026
IBSP Promotes Clear Cell Renal Cell Carcinoma Progression Through the PI3 K/AKT Pathway.
Article in Biochemical genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Our objective is to reveal IBSP expression within clear cell renal cell carcinoma (ccRCC) and the mechanism behind it. IBSP expression and its clinical significance in ccRCC were analyzed using the TCGA dataset. Both Western blotting and immunohistochemistry were utilized to examine IBSP expressions in clinical ccRCC specimens. Moreover, CCK-8, Annexin V-FITC/PI, wound healing, and Transwell assays were utilized to determine IBSP's role in ccRCC progression in vitro. In addition, Western blotting was deployed to ascertain levels of IBSP, PI3K/p-PI3K, and AKT/p-AKT. The TCGA database and our tissue data showcased that, unlike normal tissues, IBSP was significantly overexpressed in ccRCC tissues. Down-regulating IBSP reduces cell abilities to proliferate, migrate, and invade, besides promoting apoptosis in vitro. In vitro and in vivo, IBSP down-regulation inhibited ccRCC growth cells by suppressing PI3K/AKT phosphorylation. IBSP acts as a potential oncogene and could be a prognostic biomarker and therapeutic target for ccRCC. Furthermore, targeting IBSP may enhance existing treatment strategies, such as combining it with PI3K/AKT inhibitors to improve patient outcomes.
Indexed as
Identifiers
40285946What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.